BRTX
BioRestorative Therapies, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.69
+1.32%Sep 11, 2026, 13:31 UTC
Mr. Silva resigned as Vice President of Research and Development of BioRestorative Therapies, Inc., effective September 4, 2026.
Sep 10, 2026, 20:32 UTC
BioRestorative Therapies, Inc. dismissed CBIZ CPAs P.C. as its independent auditor and engaged Bush & Associates CPA, effective August 28, 2026.
Sep 2, 2026, 21:27 UTC
BioRestorative Therapies' board approved a 1-for-20 reverse stock split of its common stock, effective September 7, 2026, to regain Nasdaq compliance with the $1.00 minimum bid price requirement.
Source:Sep 2, 2026, 10:28 UTC
Katharyn Field resigned as Interim Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary and Board member of BioRestorative Therapies, effective late August 2026, with successors appointed.
Aug 25, 2026, 00:00 UTC
BioRestorative Therapies, Inc. received a notice from Nasdaq on August 21, 2026, stating it is not in compliance with Listing Rule 5250(c)(1) due to a delinquent Form 10-Q filing, and the company is working to file the report and submit a compliance plan by the October 20, 2026 deadline.
Jun 25, 2026, 12:15 UTC
BioRestorative Therapies completed manufacturing for its BRTX-100 Phase 2 clinical trial, a key milestone in developing its lead cell therapy candidate.
Source:Jun 18, 2026, 12:15 UTC
BioRestorative Therapies appointed Zachary Smith as Vice President of its Biocosmeceuticals Division.
Source: